Genfit SA GNFT:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 4:00 PM EDT
3.67quote price arrow down-0.01 (-0.27%)
Volume
668
52 week range
3.50 - 7.19
Loading...
  • Open3.67
  • Day High3.70
  • Day Low3.67
  • Prev Close3.68
  • 52 Week High7.19
  • 52 Week High Date02/10/21
  • 52 Week Low3.50
  • 52 Week Low Date07/19/21

Key Stats

  • Market Cap168.20M
  • Shares Out45.83M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta1.23
  • YTD % Change-22.94

KEY STATS

  • Open3.67
  • Day High3.70
  • Day Low3.67
  • Prev Close3.68
  • 52 Week High7.19
  • 52 Week High Date02/10/21
  • 52 Week Low3.50
  • 52 Week Low Date07/19/21
  • Market Cap168.20M
  • Shares Out45.83M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta1.23
  • YTD % Change-22.94

RATIOS/PROFITABILITY

  • EPS (TTM)-1.23
  • P/E (TTM)-3.00
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-62.57M
  • ROE (TTM)-122.45%
  • Revenue (TTM)6.14M
  • Gross Margin (TTM)72.49%
  • Net Margin (TTM)-736.08%
  • Debt To Equity (MRQ)207.89%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Genfit SA

There is no recent news for this security.

Profile

MORE
Genfit SA is a France-based biopharmaceutical company that specializes in the development of medicines for the prevention and treatment of diabetes and related disorders. The Company is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The Company targets a number of...
Jean-Francois Mouney
Chairman
Xavier Guille Des Buttes
Non-Executive Chairman
Pascal Prigent
Chief Executive Officer
Dean Hum Ph.D.
Chief Operating Officer
Thomas Baetz
Chief Financial Officer
Nathalie Huitorel
Executive Vice President
Address
Parc Eurasante 885 avenue Eugene Avinee
Loos
59120
France